Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy.
暂无分享,去创建一个
Xue Wu | Y. Shao | J. Ying | H. Bao | Qi Xu | C. Luo | Jianying Jin | Junrong Yan | Jingjing Li | Xiaoqing Xu | H. Tang | Haimin Wen
[1] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[2] J. Shim,et al. Aurora kinase A, a synthetic lethal target for precision cancer medicine , 2021, Experimental & Molecular Medicine.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] L. Shen,et al. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies , 2020, Clinical and translational medicine.
[5] V. Villegas,et al. Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines , 2020, Cancer biology & medicine.
[6] D. Lin,et al. Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers , 2020, Pathology & Oncology Research.
[7] E. Oki,et al. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). , 2018, European journal of cancer.
[8] G. Lee,et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) , 2018, Gastric Cancer.
[9] Sourav Bandyopadhyay,et al. Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer , 2018, Nature Medicine.
[10] W. Jia,et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer , 2018, Gut.
[11] Hui-Ping Zhao,et al. The Association Between AURKA Gene rs2273535 Polymorphism and Gastric Cancer Risk in a Chinese Population , 2018, Front. Physiol..
[12] T. Chan,et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab , 2017, Cell.
[13] Dan Sun,et al. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo , 2016, Oncotarget.
[14] V. Seshan,et al. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.
[15] C. Scapulatempo-Neto,et al. HER2 testing in gastric cancer: An update. , 2016, World journal of gastroenterology.
[16] A. Tesei,et al. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer , 2016, Oncotarget.
[17] Daniel Q. Naiman,et al. SubClonal Hierarchy Inference from Somatic Mutations: Automatic Reconstruction of Cancer Evolutionary Trees from Multi-region Next Generation Sequencing , 2015, bioRxiv.
[18] R. Schiff,et al. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells , 2015, Cell cycle.
[19] Teresa Palomero,et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia , 2014, Nature Medicine.
[20] A. Bouchard-Côté,et al. PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.
[21] M. Hauptmann,et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[22] P. Marignani,et al. Loss of lkb1 Expression Reduces the Latency of ErbB2-Mediated Mammary Gland Tumorigenesis, Promoting Changes in Metabolic Pathways , 2013, PloS one.
[23] M. Katoh,et al. Function and cancer genomics of FAT family genes , 2012, International journal of oncology.
[24] T. Mäkelä,et al. Molecular mechanisms of tumor suppression by LKB1 , 2011, FEBS letters.
[25] Olufunmilayo I Olopade,et al. MYC and Breast Cancer. , 2010, Genes & cancer.
[26] G. Bu,et al. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy , 2010, Proceedings of the National Academy of Sciences.
[27] F. E. Bertrand,et al. Notch‐1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression , 2009, Journal of cellular biochemistry.
[28] E. Cho,et al. HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.
[29] J. Isola,et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Hung,et al. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.
[31] D. Liao,et al. c-Myc in breast cancer. , 2000, Endocrine-related cancer.
[32] H. Ogawara,et al. Characterization of the epidermal growth factor receptor and the erbB oncogene product by site-specific antibodies. , 1986, Archives of biochemistry and biophysics.
[33] L. Shen,et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. , 2018, European journal of cancer.
[34] G. Lee,et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). , 2016, European journal of cancer.
[35] M Wang,et al. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. , 2009, Neoplasma.